ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2018
The Gut Microbiota and Pediatric Multiple Sclerosis: Recent Findings.
Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- Microbiota-gut-brain axis in health and neurological disease: Interactions between gut microbiota and the nervous system.Journal of cellular and molecular medicine · 2024Review
- Review of microbiota gut brain axis and innate immunity in inflammatory and infective diseases.Frontiers in cellular and infection microbiology · 2023Review
- Regulation of common neurological disorders by gut microbial metabolites.Experimental & molecular medicine · 2021Review
- Etiological research in pediatric multiple sclerosis: A tool to assess environmental exposures (PEDiatric Italian Genetic and enviRonment ExposurE Questionnaire).Multiple sclerosis journal - experimental, translational and clinical · 2021Article
- Unravelling the potential of gut microbiota in sustaining brain health and their current prospective towards development of neurotherapeutics.Archives of microbiology · 2021Review
- Modulating Gut Microbiota: An Emerging Approach in the Prevention and Treatment of Multiple Sclerosis.Current neuropharmacology · 2021Review
- Air pollution as a contributor to the inflammatory activity of multiple sclerosis.Journal of neuroinflammation · 2020Article
- Extra-Virgin Olive Oil Modifies the Changes Induced in Non-Nervous Organs and Tissues by Experimental Autoimmune Encephalomyelitis Models.Nutrients · 2019Article
- Altered tryptophan metabolism is associated with pediatric multiple sclerosis risk and course.Annals of clinical and translational neurology · 2018Article
- The Microbiome and Neurologic Disease: Past and Future of a 2-Way Interaction.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2018Article
- Long-Term Provision of Acidified Drinking Water Fails to Influence Autoimmune Diabetes and Encephalomyelitis.Journal of diabetes research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pediatric multiple sclerosis (MS) is a chronic, life-long neurological condition associated with inflammation and degeneration in the brain and spinal cord. Fortunately, < 5% of people with MS have their onset in childhood years. However, studying these very-early-onset cases of MS offers key advantages. In particular, with fewer years lived, children have had a limited range of exposures, potentially enhancing our ability to identify what might cause MS. Further, as the actual timing of the biological MS onset is unknown, the possibility to study these children much closer to the real onset of disease is far greater than in the typical adult with MS. Whether MS (in children or adults) can be prevented is unknown and the available drugs are only modestly effective in modifying the disease course and are not without risk. Emerging evidence is providing insight into the gut microbiota's potential role in triggering and shaping neurological conditions such as MS. The limited number of studies in humans with MS and absence of prior work in pediatric MS motivated the following 3 fundamental questions, addressed in 2 cross-sectional and 1 longitudinal investigation in children with and without MS: 1) Does the gut microbiota composition differ between children with and without MS? 2) Is there an association between the gut microbiota and host immune markers in children with and without MS? 3) Is the gut microbiota associated with the future risk of a MS relapse?
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.